

Delivered by directly [to] contacting the [endothelium] endothelial cells of large vessels with the nucleic acid molecule conjugate, either *in vitro*, by catheterization to the endothelial cells, or during a surgical procedure involving the endothelial cells to be contacted.

6. (twice amended) The method of claim [1] 5 wherein the [molecule to be delivered is a nucleic acid molecule and the] nucleic acid molecule is selected from the group consisting of triplex forming oligonucleotides, ribozymes, guide sequences for ribozymes, and antisense [and the nucleic acid molecule is delivered directly to the endothelium of large vessels].

7. (amended) The method of claim 1 wherein the molecule to be delivered is selected from the group consisting of non-nucleic acid drugs and diagnostic agents.

13. (amended) A conjugate of an agent binding selectively to endothelial protein C receptor (EPCR) selected from the group consisting of protein C, activated protein C, antibodies reactive with EPCR and fragments thereof binding to EPCR, and a molecule to be delivered to a large vessel endothelial cell, wherein the molecule is not a diagnostic label.

16. (three times amended) The conjugate of claim 13 wherein the molecule to be delivered is a nucleic acid molecule in combination with means for [delivering] directly contacting the nucleic acid molecule conjugate directly with [to] the [endothelium] endothelial cells of large vessels, wherein the means are for *in vitro* treatment of the cells, for catheterization to the endothelial cells, or for performing a surgical procedure involving the endothelial cells to be contacted.

17. (twice amended) The conjugate of claim 16 wherein the nucleic acid molecule is a gene or cDNA under the control of a promoter expressed in the nucleus of an endothelial cell [in combination with means for delivering the nucleic acid molecule directly to the endothelium of large vessels].